Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed prostate cancer~  * Metastatic disease, as demonstrated by bone scan and/or CT scan of the abdomen/pelvis~ * Must demonstrate disease progression after initial hormone therapy (including bicalutamide and flutamide)~ * No prior chemotherapy allowed~* No known brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 6 months~* ANC \> 1,500/μL~* Hemoglobin \> 10 g/dL~* Platelet count \> 100,000/mm\^3~* Serum creatinine \< 2.0 mg/dL or creatinine clearance \> 50 mL/min~* Total bilirubin normal~* SGOT and/or SGPT \< 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase \< 2.5 times ULN~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy~* No second primary malignancy except for most in situ carcinomas (e.g., adequately treated nonmelanoma carcinoma of the skin) or other malignancy treated ≥ 5 years ago with no evidence of recurrence~* No history or symptoms of cardiovascular disease, including any of the following:~  * NYHA class II-IV cardiovacular disease within the past 6 months~ * Coronary artery disease~ * Arrhythmias~ * Conduction defects with risk of cardiovascular instability~ * Uncontrolled hypertension~ * Clinically significant pericardial effusion~ * Congestive heart failure~* No uncontrolled intercurrent illness including ongoing active infection that would limit compliance with study requirements~* No rheumatoid arthritis or systemic lupus erythematosus requiring treatment~* No psoriasis or porphyria~* No known HIV infection~* No hypersensitivity to 4-aminoquinoline compounds, including hydroxychloroquine sulfate, chloroquine phosphate, and amodiaquine~* No retinal or vision changes from prior 4-aminoquinoline compound use~* No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* No known G-6PDH deficiency~* Neurotoxicity ≤ grade 1~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from all prior therapy~* No prior taxane~* At least 4 weeks since prior therapy (including surgery and radiotherapy)~* At least 1 week since prior herbal supplements~* At least 6 weeks since prior bicalutamide~* At least 4 weeks since prior flutamide~* No current hydroxychloroquine for treatment or prophylaxis~  * Prior hydroxychloroquine allowed~* No other concurrent investigational or commercial agents or therapies, including chemotherapy, immunotherapy, hormonal cancer therapy, radiotherapy, surgery for cancer, or experimental therapy~* Concurrent luteinizing-hormone releasing-hormone agonists allowed

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Docetaxel and Hydroxychloroquine (Type: EXPERIMENTAL): Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycle~Drug: hydroxychloroquine 200 mg twice daily~A cycle is defined as an interval of 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).